Sildenafil

From Citizendium
Revision as of 16:37, 21 June 2008 by imported>David E. Volk (chemistry and drug interactions)
Jump to navigation Jump to search
This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
Sildenafil3.jpg
sildenafil
IUPAC name: see Chemistry
Synonyms: Viagra®
Formula:

 Uses: Erectile Dysfunction

 Properties: PDE-5 inhibitor

 Hazards: cardiovascular risks

Mass (g/mol): CAS #:
666.7 (citrate)


Sildenafil, widely known as Viagra®, is a medication used to treat erectile dysfunction. It is also marketed as Ravatio® as an oral treatment for pulmonary arterial hypertension. Both drugs are sold as the citrate salt of sildenafil. It was the first commercialized selective phosphodiesterase type 5 (PDE-5) inhibitor and was immediately popular both for treating erectile dysfunction and for recreational use. Sildenafil works by binding to phosphodiesterase type-5 enzymes, competing with the natural ligand cyclic guanine monophosphate (cGMP), which is structurally similar to sildenafil. Vardenafil, a newer and more potent PDE-5 inhibitor, is nearly identical to sildenafil, while tadalafil is considerably different in structure.

Chemistry

The IUPAC name of sildenafil is 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d] pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine and it has a molecular mass of 666.7 g/mol (as the citrate salt).

Drug interactions

Because sildenafil has vasodilator properties that result in decreased blood pressure, the combined use of sildenafil with other vasodilators, such as alpha-blockers, must be done cautiously. Patients with a history of heart attacks, strokes, arrythmia, hypertension, retinitis pigmentosa or currently on bosentan therapy.

Up-to-Date Information

The most up-to-date information about this and other drugs can be found at the following sites.

References

J. D. Corbin and S. H. Sharron. "Molecular Biology and Pharmacology of PDE-5-Inhibitor Therapy for Erectile Dysfunction". J. Androl. 24: S38-S41.